 | Up a level |
Merola, E; Pascher, A; Rinke, A; Bartsch, D K; Zerbi, A; Nappo, G; Carnaghi, C; Ciola, M; McNamara, M G; Zandee, W; Bertani, E; Marcucci, S; Modica, R; Grützmann, R; Fazio, N; de Herder, W; Valle, J W; Gress, T M; Fave, G Delle; de Pretis, G; ... (2022). Radical Resection in Entero-Pancreatic Neuroendocrine Tumors: Recurrence-Free Survival Rate and Definition of a Risk Score for Recurrence. Annals of surgical oncology, 29(9), pp. 5568-5577. Springer 10.1245/s10434-022-11837-1
Merola, E; Pascher, A; Rinke, A; Bartsch, D K; Zerbi, A; Nappo, G; Carnaghi, C; Ciola, M; McNamara, M G; Zandee, W; Bertani, E; Marcucci, S; Modica, R; Grützmann, R; Fazio, N; de Herder, W; Valle, J W; Gress, T M; Delle Fave, G; de Pretis, G; ... (2022). ASO Visual Abstract: Radical Resection in Enteropancreatic Neuroendocrine Tumors-Recurrence-Free Survival Rate and Definition of a Risk Score for Recurrence. Annals of surgical oncology, 29(9), pp. 5580-5581. Springer 10.1245/s10434-022-12049-3
Kianmanesh, R; Ruszniewski, P; Rindi, G; Kwekkeboom, D; Pape, UF; Kulke, M; Sevilla Garcia, I; Scoazec, JY; Nilsson, O; Fazio, N; Lesurtel, M; Chen, YJ; Eriksson, B; Cioppi, F; O'Toole, D; Palma de Mallorca Consensus Conference Participiants, (Perren A) (2010). ENETS consensus guidelines for the management of peritoneal carcinomatosis from neuroendocrine tumors. Neuroendocrinology, 91(4), pp. 333-340. Basel: Karger 10.1159/000286700
Roth, AD; Fazio, N; Stupp, R; Falk, S; Bernhard, J; Saletti, P; Köberle, D; Borner, MM; Rufibach, K; Maibach, R; Wernli, M; Leslie, M; Glynne-Jones, R; Widmer, L; Seymour, M; de Braud, F; Swiss, Group for Clinical Cancer Research (2007). Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research. Journal of clinical oncology, 25(22), pp. 3217-23. Alexandria, Va.: American Society of Clinical Oncology 10.1200/JCO.2006.08.0135
